Board of Directors

	Peter Fellner, Chairman of the Board Born: 1943 Education: Ph.D. in molecular biology Board member since October 2009 Principal occupation: Company Director Employment history: CEO of Celltech Group Plc from 1990 to 2003, and its Chairman until 2004. CEO of Roche UK from 1986 to 1990. Also served as a Director of a number of other public companies. Key position of trust: Chairman of Consort Medical Plc, Chairman of Optos Plc, Chairman of Vernalis Plc, Chairman of Astex Therapeutics Ltd, Vice-Chairman Astex Pharmaceuticals Inc., Director of UCB SA, Director of Evotec AG Number of shares held in Biotie
	Merja Karhapää Born: 1962 Education: LL.M. (Helsinki University) and Postgraduate IPR Diploma (Bristol University) Board member since April 2010 Principal occupation: Chief Legal Officer (CLO, Group Legal Affairs) and Company Secretary(since 2008) Employment history: Sanoma Corporation since 2000 as Vice President, Group Legal Affairs. Vice President, Intellectual Capital of Danisco, Trademark Counsel and Assistant General Counsel of Cultor and Danisco in 1996-2000 and as Corporate Counsel of Sanoma(former Sanoma News) and Valmet. Key positions of trust: Helsingin Sanomat Foundation deputy member, Market Court expert member (competition matters), Chairman of the Central Chamber of Commerce IPR Committee and Finnish IPR Forum, Confederation of Finnish Industries IPR Committee member, Confederation of Finnish Industries Law Committee member, Ministry of Education Copyright Commission member Number of shares held in Biotie
	Bernd Kastler Born: 1949 Education: Doctorate in law in 1980 from the University of Giessen (Germany). Board member since November 2008 Principal occupation: Company Director Employment history: Co-founder and from 2002 until 2008 CEO of elbion NV. From 1989 until 2002 Member of the Executive Board of ASTA Medica AG, the pharmaceutical subsidiary of Degussa AG. His responsibilities included the fi nance and the human resources areas. Between 1979 and 1989 different positions at Degussa AG. Key positions of trust: Kastler GmbH, controlled company Number of shares held in Biotie
	Piet Serrure Born: 1954 Education: M.Sc. (Econ.) Board member since March 2004 Principal occupation: Becap Bvba, Managing Director since 2006 Employment history: Origo Management, Managing Director 2001–2006. Parnib (NIB Capital), Director and CEO until 2001. Benevent (venture capital company) 1985-1992. Different positions at Du Pont de Nemours and Arthur Andersen. 1976–1985. European Private Equity and Venture Capital Association (EVCA), Member of the Board of Directors until 2004. Key positions of trust: Europe Unlimited, Chairman of the Board of Directors. Member of the Board of Directors at Fin. Co, IPTE, Visys and Hybrigenics. Number of shares held in Biotie
	James S. Shannon Born: 1956 Education: Doctor of Medicine Board member since April 2010 Principal occupation: Company Director Employment history: Novartis Pharma from 1995 to 2008 most recently as Global Head, Pharma Development. Prior to this he was with Sterling research group from 1987 to 1994. Key positions of trust: Circassia, Endocyte, Mannkind, Xanodyne Number of shares held in Biotie
	Bradley J. Bolzon Born: 1959 Education: Doctor of Philosophy, Pharmacology Board member since February 2011 Principal occupation: Managing Director of Versant Ventures Employment history: Roche Pharma from 2000 to 2004, most recently as Executive Vice President, Global Head of Business Development, Licensing and Alliances. Prior to this he was with Eli Lilly from 1995 to 2000 in various roles including Director of Business Development and head of Cardiovascular Research. Key positions of trust: Chairman of the Board of Synosia Therapeutics Holding AG, Chairman of Versant EuroVentures, Chairman of the Board of Amira and Flexion, Director of Metabolex, Anaphore, and Okairos Number of shares held in Biotie
	Andrew J. Schwab Born: 1971 Education: BS in Genetics and Ethics Board member since February 2011 Principal occupation: Founder and Managing Partner of 5AM Ventures Employment history: Principal at Bay City Capital from 1999 to 2002, Vice President at Montgomery Securities from 1994 to 1998 Key positions of trust: Director of Anaphore, DVS Sciences, Flexion, Viveve and Cleave Biosciences Number of shares held in Biotie
	Guido Magni Born: 1953 Education: Doctor of Medicine, Doctor of Philosophy Board member since February 2011 Principal occupation: Managing Director of Versant Euro Ventures Employment history: Hoffman La Roche from 1993 to 2008, first as Global Head of CNS Development and from 1995 to 2008 as Global Head of Medical Science, Global Drug Development, Pharmaceuticals Division, he was also a member of the R&D Board, the Life Cycle Committee and the Business Development Board. Prior to joining Roche Dr. Magni was with Wyeth-Ayerst where he served in clinical development as CNS Therapeutic Area Head, Europe Key positions of trust: Director of Anabasis Number of shares held in Biotie Maximum number of shares to be subscribed based on option rights: 134 592 Option program: Swiss option plan
	Ismail Kola Born: 1957 Education: Doctor of Medicine Board member since February 2011 Principal occupation: Executive Vice President of UCB Pharma and President of New MedicinesTM UCB Pharma Employment history: Schering Plough Corporation from 2007 to 2009 where he was Senior Vice President, Discovery Research and Early Clinical Research & Experimental Medicine, Schering Plough Research Institute, the pharmaceutical research arm of Schering Plough Corporation. He was also Chief Scientific Officer of Schering Corporation Inc. Dr. Kola came to Schering Plough from Merck, where he was Senior Vice president and Site Head, Basic Research. He also chaired Merck’s Antibacterial and Antifungal Worldwide Business Strategy Team. Prior to that he was Vice President, Research, and Global Head, Genomics Science and Biotechnology, with Pharmacia Corporation, and served as a consultant to SmithKline Beecham Pharmaceuticals. Dr. Kola was a professor of Human Molecular Genetics, Monash University Medical School for 15 years and Director of the Research Center for functional Genomics and Human Disease. He holds Adjunct Professorships of Medicine at Washington University, St Louis, Missouri, USA, and Monash University Medical School, Melbourne, Australia; a Foreign Adjunct at the Karolinska Institute, Stockholm, Sweden; and is William Pitt Fellow at Pembroke College, Cambridge University, UK. Key positions of trust: Member of the Board of Directors of Athersys (ATHX – Nasdaq); Member of the Board of Directors of Astex (ASTX – Nasdaq). Number of shares held in Biotie
	William M. Burns Born: 1947 Education: Bachelor of Art, Honours Degree Board member since February 2011 Principal occupation: Member of the Board of Directors Roche and Shire PLC Employment history: Roche from 1986 to 2010, most recently as Chief Executive Officer of the Division of Roche Pharmaceuticals. Prior to this Mr. Burns held senior positions with Roche including Head of the Pharmaceuticals Division, Head of Pharma Europe, and Global Head of Strategic Marketing & Business Development. Prior to joining Roche Mr Burns spent 17 years with Beecham Pharmaceuticals in the UK and Japan where he held a variety of positions. Key positions of trust: Member of the Board of Directors of Chugai from 2002, Member of the Board of Directors of Genentech from 2004 to 2009 Number of shares held in Biotie ---- Updated February 3, 2012